Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AERIE PHARMACEUTICALS INCAERI · Entity 122210 | Chief R&D Officer | February 04, 2022 | February 08, 2022 |
| KIORA PHARMACEUTICALS INCKPRX · Entity 7940 | Director | June 10, 2026 | June 12, 2026 |
| Veradermics, IncMANE · Entity 1907 | Chief R&D Officer | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AERIE PHARMACEUTICALS INC
Report date February 04, 2022 · Filed February 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,749 |
Reported balance
After 2022-02-04 transaction · row 1
1 source rowRow 1 · 2022-02-04 · Tax withholding · Disposed 927 · Balance 30,749 F1: Reflects shares of Common Stock withheld to satisfy tax withholding obligations in connection with the vesting of shares of restricted Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects shares of Common Stock withheld to satisfy tax withholding obligations in connection with the vesting of shares of restricted Common Stock.
KIORA PHARMACEUTICALS INC
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.63 · Expires 2036-06-10 | Direct | 25,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 25,000 · Balance 25,000 F1: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027.
Veradermics, Inc
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,650 |
Reported balance
After 2026-09-01 transaction · row 1
1 source rowRow 1 · 2026-09-01 · Grant · Acquired 9,650 · Balance 9,650 F1: These shares represent restricted stock units (RSUs) granted under the Veradermics, Incorporated 2026 Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest as to 25% of the RSUs on each anniversary of the grant date (September 1, 2027, September 1, 2028, September 1, 2029, and September 1, 2030), subject to continued service. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $97.51 · Expires 2036-09-01 | Direct | 19,300 |
Reported balance
After 2026-09-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-01 · Grant · Acquired 19,300 · Balance 19,300 F2: The option vests as to 25% of the underlying shares of Common Stock on September 1, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units (RSUs) granted under the Veradermics, Incorporated 2026 Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest as to 25% of the RSUs on each anniversary of the grant date (September 1, 2027, September 1, 2028, September 1, 2029, and September 1, 2030), subject to continued service.
F2: The option vests as to 25% of the underlying shares of Common Stock on September 1, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Revance Therapeutics, Inc.
Report date February 04, 2025 · Filed February 06, 2025
Section 16 reporting ended · disclosed 2025-02-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-02-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-04 · Other · Disposed 9,733 · Balance 95,212 F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer. Row 2 · 2025-02-06 · Disposition to issuer · Disposed 95,212 · Balance 0 F2: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") award then outstanding and not vested was canceled and converted into the right to receive an amount in cash, without interest thereon and subject to applicable withholding taxes, equal to the product of the Per Share Price and the total number of Shares subject to such unvested RSU award as of immediately prior to the Effective Time (as defined in the Merger Agreement). |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer.
F2: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") award then outstanding and not vested was canceled and converted into the right to receive an amount in cash, without interest thereon and subject to applicable withholding taxes, equal to the product of the Per Share Price and the total number of Shares subject to such unvested RSU award as of immediately prior to the Effective Time (as defined in the Merger Agreement).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 3, 2026 20:35 UTC | Veradermics, Inc MANE · Entity 1907 | GrantStock Option (Right to Buy) · Derivative | 19,300 | $0.00 Strike: $97.51 | $0.00 |
DisclosureSEC source: 0001628280-26-060491 · wk-form4_1788467701.xml · derivative · entry 2 Hollander David · CIK 0001793796 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,300 Underlying: Common Stock · 19,300 shares Expires 2036-09-01 F2 · derivative.exercise_date: The option vests as to 25% of the underlying shares of Common Stock on September 1, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:35 UTC | Veradermics, Inc MANE · Entity 1907 | GrantCommon Stock | 9,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-060491 · wk-form4_1788467701.xml · nonDerivative · entry 1 Hollander David · CIK 0001793796 · Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,650 F1 · shares: These shares represent restricted stock units (RSUs) granted under the Veradermics, Incorporated 2026 Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest as to 25% of the RSUs on each anniversary of the grant date (September 1, 2027, September 1, 2028, September 1, 2029, and September 1, 2030), subject to continued service. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:15 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001793796-26-000002 · wk-form4_1781295336.xml · derivative · entry 1 Hollander David · CIK 0001793796 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 00:15 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001372514-25-000028 · wk-form4_1743639302.xml · derivative · entry 1 Hollander David · CIK 0001793796 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-04-01 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on April 1, 2026. Read SEC document |
| February 06, 2025 Filed Feb 6, 2025 15:58 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Disposition to issuerCommon Stock | 95,212 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-015359 · ownership.xml · nonDerivative · entry 2 Hollander David · CIK 0001793796 · CMO & Global Therapeutics Lead 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") award then outstanding and not vested was canceled and converted into the right to receive an amount in cash, without interest thereon and subject to applicable withholding taxes, equal to the product of the Per Share Price and the total number of Shares subject to such unvested RSU award as of immediately prior to the Effective Time (as defined in the Merger Agreement). Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 15:58 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | OtherCommon Stock | 9,733 | $3.65 | $35,525.45 |
DisclosureSEC source: 0000950170-25-015359 · ownership.xml · nonDerivative · entry 1 Hollander David · CIK 0001793796 · CMO & Global Therapeutics Lead 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,212 F1 · kind: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer. Read SEC document |
| November 18, 2024 Filed Nov 19, 2024 16:31 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 3,908 | $4.17 | $16,296.36 |
DisclosureSEC source: 0001479290-24-000130 · wk-form4_1732051887.xml · nonDerivative · entry 1 Hollander David · CIK 0001793796 · CMO & Global Therapeutics Lead 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,945 F1 · shares: Represents the number of shares required to be sold by the Reporting Person, to cover tax withholding obligations in connection with the vesting of restricted stock units granted on October 17, 2022 which vest in equal installments over a four year period. This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 19:15 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 1,778 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001372514-24-000089 · wk-form4_1720034119.xml · derivative · entry 1 Hollander David · CIK 0001793796 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,778 Underlying: Common Stock · 1,778 shares Expires 2034-07-01 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on July 1, 2025. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 20:44 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 0 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001372514-23-000144 · wk-form4_1696365864.xml · derivative · entry 1 Hollander David · CIK 0001793796 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2033-09-29 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on September 29, 2024. Read SEC document |
| March 03, 2023 Filed Mar 8, 2023 01:13 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $3.83 | $0.00 |
DisclosureSEC source: 0001372514-23-000030 · wf-form4_167823801678609.xml · derivative · entry 1 Hollander David · CIK 0001793796 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2033-03-03 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on March 3, 2024. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 20:40 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | Tax withholdingCommon Stock | 927 | $7.05 | $6,535.35 |
DisclosureSEC source: 0001209191-22-007902 · doc4.xml · nonDerivative · entry 1 Hollander David · CIK 0001793796 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,749 F1 · shares: Reflects shares of Common Stock withheld to satisfy tax withholding obligations in connection with the vesting of shares of restricted Common Stock. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:02 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001104659-22-011492 · tm225348d3_4.xml · derivative · entry 2 Hollander David · CIK 0001793796 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2032-02-01 F2 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become fully exercisable on February 1, 2023. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:02 UTC | KIORA PHARMACEUTICALS INC KPRX · Entity 7940 | GrantStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001104659-22-011492 · tm225348d3_4.xml · derivative · entry 1 Hollander David · CIK 0001793796 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan in connection with the Reporting Person's appointment to the Issuer's Board of Directors. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2023, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 16:44 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | Tax withholdingCommon Stock | 2,162 | $12.06 | $26,073.72 |
DisclosureSEC source: 0001209191-21-064473 · doc4.xml · nonDerivative · entry 1 Hollander David · CIK 0001793796 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,676 F1 · shares: Reflects shares of Common Stock withheld to satisfy tax withholding obligations in connection with the vesting of shares of restricted Common Stock. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 18:07 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $17.64 | $0.00 |
DisclosureSEC source: 0001209191-21-008586 · doc4.xml · derivative · entry 2 Hollander David · CIK 0001793796 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-02-04 F2 · derivative.exercise_date: This option is scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting date, in equal installments on each of the first 48 monthly anniversaries of February 4, 2021. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 18:07 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantCommon Stock | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008586 · doc4.xml · nonDerivative · entry 1 Hollander David · CIK 0001793796 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,838 F1 · shares: These shares of Common Stock are scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting date, in equal installments on each of the first four anniversaries of February 4, 2021. Read SEC document |
| November 11, 2020 Filed Nov 12, 2020 17:05 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | Tax withholdingCommon Stock | 2,162 | $13.05 | $28,214.10 |
DisclosureSEC source: 0001209191-20-058030 · doc4.xml · nonDerivative · entry 1 Hollander David · CIK 0001793796 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,838 F1 · shares: Reflects shares of Common Stock withheld to satisfy tax withholding obligations in connection with the vesting of shares of restricted Common Stock. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 16:08 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantStock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $19.05 | $0.00 |
DisclosureSEC source: 0001209191-19-056323 · doc4.xml · derivative · entry 2 Hollander David · CIK 0001793796 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2029-11-11 F2 · derivative.exercise_date: This option was granted under the Plan and is scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting date, as to 25% of the underlying shares on November 11, 2020 and as to the remaining underlying shares in substantially equal installments on each of the first 36 monthly anniversaries of November 11, 2020. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 16:08 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-056323 · doc4.xml · nonDerivative · entry 1 Hollander David · CIK 0001793796 · Chief R&D Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · shares: These shares of Common Stock were granted under the Aerie Pharmaceuticals, Inc. Amended and Restated Inducement Award Plan (the "Plan") and are scheduled to vest, subject to the reporting person's continued employment with the issuer through the applicable vesting date, in equal installments on each of the first four anniversaries of November 11, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.